
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has raised its 2025 revenue guidance to a range of $5,050-5,150 million, indicating a consistent growth forecast of 5-7% in constant currency. The company is projected to achieve an adjusted EBITDA between $860-910 million, highlighting operational efficiency and financial health. Key product lines, such as MIEBO and XIIDRA, have shown significant year-over-year prescription growth, underscoring the strength of Bausch & Lomb's diverse portfolio and market position in the vision care sector.
Bears say
Bausch & Lomb’s financial outlook presents several concerns that contribute to a negative assessment of the stock. Despite reporting revenue growth in its Vision Care and Surgical segments, the Pharmaceuticals segment showed a slight decline, and persistent pricing pressure on key products like XIIDRA raises concerns about future revenue stability. Additionally, the company's high debt levels resulting from its acquisition of XIIDRA, coupled with a limited product pipeline and competitive pressures, further threaten its long-term growth prospects.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares